Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05635838 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT05635838 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 69 participants.
The verdict
NCT05635838, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.
Interventions
- DRUG Vehicle cream
- DRUG Ruxolitinib cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2024-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05635838
The ClinicalTrials.gov registry entry for NCT05635838 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle cream is the first listed.
NCT05635838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05635838 about?
NCT05635838 is a clinical study titled "Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa". The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for partici...
What is the current status of trial NCT05635838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2022-12-07. Estimated completion is 2024-03-14.
What interventions are being tested in trial NCT05635838?
The interventions under investigation include: Vehicle cream (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT05635838?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.